Pink1 deficiency sustains cell proliferation by reprogramming glucose metabolism through hif1

Nature Communications

Volumn 5, Issue , 2014, Pages

  Requejo Aguilar, Raquel ^a,b   Lopez Fabuel, Irene ^a,b   Fernandez, Emilio ^a,b   Martins, Luis M ^c   Almeida, Angeles ^a,b   Bolaños, Juan P ^a,b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA IBSAL   (Spain)

^c MRC TOXICOLOGY UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE 6 PHOSPHATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE DEHYDROGENASE KINASE 1; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ENZYME; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HIF1A PROTEIN, MOUSE; PROTEIN KINASE; PTEN-INDUCED PUTATIVE KINASE; SLC2A1 PROTEIN, MOUSE; SLC2A3 PROTEIN, MOUSE;

ENZYME ACTIVITY; GLUCOSE; METABOLISM; MITOCHONDRION; NEUROLOGY; RODENT;

ANIMAL CELL; ARTICLE; BRAIN CELL; CELL CULTURE; CELL CYCLE PHASE; CELL GROWTH; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; ENZYME DEFICIENCY; FIBROBLAST; GLUCOSE INTAKE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCOLYSIS; IN VIVO STUDY; MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PENTOSE PHOSPHATE CYCLE; PHENOTYPE; PROGENY; PROTEIN STABILITY; PTEN INDUCED KINASE 1 DEFICIENCY; RESPIRATORY CHAIN; RNA INTERFERENCE; SUBVENTRICULAR ZONE; UPREGULATION; ANIMAL; C57BL MOUSE; DEFICIENCY; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; NERVE CELL;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; ENZYMES; FIBROBLASTS; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 3; GLYCOLYSIS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOCHONDRIA; NEURONS; PROTEIN KINASES; REACTIVE OXYGEN SPECIES;

EID: 84904968146     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5514     Document Type: Article

References (34)

1. Exner, N., Lutz, A. K., Haass, C. &Winklhofer, K. F. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J. 31, 3038-3062 (2012).
2. Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608 (1998). (Pubitemid 28207717)
3. Valente, E. M. et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158-1160 (2004). (Pubitemid 38661852)
4. Beilina, A. et al. Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc. Natl Acad. Sci. USA 102, 5703-5708 (2005). (Pubitemid 40559623)
5. Clark, I. E. et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441, 1162-1166 (2006). (Pubitemid 43990738)
6. Park, J. et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441, 1157-1161 (2006). (Pubitemid 43990737)
7. Corti, O. & Brice, A. Mitochondrial quality control turns out to be the principal suspect in parkin and PINK1-related autosomal recessive Parkinson's disease. Curr. Opin. Neurobiol. 23, 100-108 (2013).
8. Dagda, R. K. et al. Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. J. Biol. Chem. 284, 13843-13855 (2009).
9. Hasson, S. A. et al. High-content genome-wide RNAi screens identify regulators of parkin upstream of mitophagy. Nature 504, 291-295 (2013).
10. McCoy, M. K. & Cookson, M. R. Mitochondrial quality control and dynamics in Parkinson's disease. Antioxid. Redox. Signal. 16, 869-882 (2012).
11. Gegg, M. E., Cooper, J. M., Schapira, A. H. & Taanman, J. W. Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells. PLoS ONE 4, e4756 (2009).
12. Morais, V. A. et al. Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function. EMBO Mol. Med. 1, 99-111 (2009).
13. Unoki, M. & Nakamura, Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20, 4457-4465 (2001). (Pubitemid 32772428)
14. Lunt, S. Y. & Vander Heiden, M. G. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27, 441-464 (2011).
15. Herrero-Mendez, A. et al. The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/CCdh1. Nat. Cell Biol. 11, 747-752 (2009).
16. Semenza, G. L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Invest. 123, 3664-3671 (2013).
17. Camps, C. et al. Integrated analysis of microRNA and mRNA expression and association with HIF binding reveals the complexity of microRNA expression regulation under hypoxia. Mol. Cancer 13, 28 (2014).
18. Gandhi, S. et al. PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol. Cell 33, 627-638 (2009).
19. Kim, J. W., Tchernyshyov, I., Semenza, G. L. & Dang, C. V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3, 177-185 (2006).
20. Brunelle, J. K. et al. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab. 1, 409-414 (2005). (Pubitemid 43960624)
21. Calvani, M., Comito, G., Giannoni, E. & Chiarugi, P. Time-dependent stabilization of hypoxia inducible factor-1alpha by different intracellular sources of reactive oxygen species. PLoS ONE 7, e38388 (2012).
22. Patten, D. A. et al. Hypoxia-inducible factor-1 activation in nonhypoxic conditions: the essential role of mitochondrial-derived reactive oxygen species. Mol. Biol. Cell 21, 3247-3257 (2010).
23. Quintana-Cabrera, R. et al. g-Glutamylcysteine detoxifies reactive oxygen species by acting as glutathione peroxidase-1 cofactor. Nat. Commun. 3, 718 (2012).
24. Priyadarshini, M., Tuimala, J., Chen, Y. C. & Panula, P. A zebrafish model of PINK1 deficiency reveals key pathway dysfunction including HIF signaling. Neurobiol. Dis. 54, 127-138 (2013).
25. Lin, W. et al. Loss of PINK1 attenuates HIF-1alpha induction by preventing 4E-BP1-dependent switch in protein translation under hypoxia. J. Neurosci. 34, 3079-3089 (2014).
26. Scheele, C. et al. Altered regulation of the PINK1 locus: a link between type 2 diabetes and neurodegeneration? FASEB J. 21, 3653-3665 (2007). (Pubitemid 350075153)
27. Prestel, J. et al. Clinical and molecular characterisation of a Parkinson family with a novel PINK1mutation. J. Neurol. 255, 643-648 (2008).
28. Devine, M. J., Plun-Favreau, H. & Wood, N. W. Parkinson's disease and cancer: two wars, one front. Nat. Rev. Cancer 11, 812-823 (2011).
29. Franks, P. W. et al. Genomic variants at the PINK1 locus are associated with transcript abundance and plasma nonesterified fatty acid concentrations in European whites. FASEB J. 22, 3135-3145 (2008).
30. Tufi, R. et al. Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson's disease. Nat. Cell Biol. 16, 157-166 (2014).
31. Brix, B., Mesters, J. R., Pellerin, L. & Johren, O. Endothelial cell-derived nitric oxide enhances aerobic glycolysis in astrocytes via HIF-1alpha-mediated target gene activation. J. Neurosci. 32, 9727-9735 (2012).
32. Bolaños, J. P., Peuchen, S., Heales, S. J. R., Land, J. M. & Clark, J. B. Nitric oxide-mediated inhibition of the mitochondrial respiratory chain in cultured astrocytes. J. Neurochem. 63, 910-916 (1994). (Pubitemid 24266603)
33. Paxton, R. & Sievert, L. M. An improved assay for pyruvate dehydrogenase in liver and heart. Biochem. J. 277, 547-551 (1991).
34. Lowry, O. H., Rosebrough, N. J., Lewis-Farr, A. & Randall, R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275 (1951).